Global Rapid Infuser Market Report and Forecast 2024-2032

Global Rapid Infuser Market Outlook

The global rapid infuser market size was valued at USD 987.7 million in 2023, driven by the increasing cases of hypothermia globally. The market size is anticipated to grow at a CAGR of 4.2% during the forecast period of 2024-2032 to achieve a value of USD 1429.9 million by 2032.

Global Rapid Infuser Market Overview

Rapid infusers are used to warm liquids in emergency medical conditions and surgeries such as haemorrhage. The rapid infuser system may continuously administer human bodily fluid in a slow to quick flow. It is typically used in emergencies to provide effective and safe therapy to patients who are suffering from severe blood loss or hypovolemic shock. There are two types of rapid infuser devices, some of them are powered by a compressor while others are connected to hospital wall-pressured outlets.

The increasing cases of hypothermia, chronic pulmonary diseases, and surgical site infections are directly contributing to the rapid infuser market growth. Rapid infusers are the most convenient and efficient means of providing bodily fluids to patients in an instant. Hence, they are extensively used in anaesthetic centres as a treatment alternative. The demand for rapid infusers is also increasing with the number of ambulatory healthcare facilities. As accident cases are rising, they directly fuel the market demand.

The market is further driven by the rising research activities to improve the efficacy of rapid infusers. There is a growing integration of advanced technologies, expected to propel the market expansion. The market may also be influenced by increased competition among companies providing devices with enhanced features that minimize negative effects on blood components.

Surge in FDA Approvals to Meet the Rising Rapid Infuser Market Demand

In August, 2023, ICU Medical Inc., a worldwide leader in the development, manufacture, and sale of innovative medical devices, announced that the company has received 510(k) regulatory clearance from the U.S. Food and Drug Administration (FDA) for the Plum Duo infusion pump with LifeShield infusion safety software. The Plum Duo pump and LifeShield software will be made available to customers in the United States by early 2024.

This approval marks a significant milestone for ICU Medical Inc. and exhibits their dedication to providing safe and advanced medical devices. The market is expected to be bolstered by this FDA approval as it will provide healthcare professionals with a technologically advanced and safe solution in the form of the Plum Duo infusion pump, along with an additional layer of safety with LifeShield infusion safety software.

Innovative Product Launches to Boost the Rapid Infuser Market Share 

In April 2023, Eitan Medical, a global leader in advanced infusion therapy and drug delivery solutions with reliable innovations, announced the launch of its new cutting-edge connected infusion multi-therapy ambulatory infusion system – Avoset™. It is designed to transform post-acute care and specialty infusion therapy with compact and simplified technology that can monitor infusion treatment data remotely, aiming to enhance patient safety and improve the user experience.

 
The Avoset™ Infusion Platform complements the Sapphire Infusion portfolio and is especially well positioned to address infusion needs for therapies that require secure medication reservoirs and a long battery life at low flow rates. The Avoset Infusion Pump is MDR certified and is currently available in selected European countries.   The major offering of the product is its ability to monitor infusion treatment data remotely, allowing healthcare professionals to keep track of patient progress and enhance it. This will result in increased adoption of the system by healthcare professionals in clinical settings, contributing to the increased demand, and propelling the rapid infuser market size.

Additionally, in January 2024, Switzerland-based medical devices maker PharmaSens applied for US Food and Drug Administration (FDA) for its ‘niia essential’ insulin patch pump system. It is a significant move for PharmaSens as it is an advancing insulin pump technology, also claimed to be one of the most compact patch pumps available. It incorporates an automatic needle insertion mechanism, ensuring the safety of the 90° steel needle. The semi-reusable concept of the insulin pump system aligns with cost-efficiency and sustainable design, meeting the demand for environmentally friendly products.  These features could be the major reason for the increased adoption of this system in the forecast period.

Global Rapid Infuser Market Segmentation

Market Breakup by Type

• Trolley Mounted Devices

• Handheld Devices

Market Breakup by Usability
 

• Single Use

• Reusable

Market Breakup by Applications

• Cancer

• Diabetes

• Pediatric

• Others

Market Breakup by End Users

• Hospitals

• Ambulatory Services

• Specialty Clinics

• Others

Market Breakup by Region

• North America

• Europe

• Asia Pacific

• Latin America

• Middle East and Africa

Global Rapid Infuser Market Regional Analysis

Geographically, North America is leading the global market rapid infuser market share and is expected to lead throughout the forecast period. This is due to access to advanced and innovative technologies associated with healthcare and effective healthcare regulations, contributing to the market growth in the region.

In November 2023, 410 Medical, Inc., focused on early resuscitation of emergency patients with shock and hypotension, announced the completion of an Air Force AFWERX Phase II SBIR Award to advance the development of LifeFlow Ultra. This innovative ultra-compact rapid infuser is designed for operational environments where space, weight, and power supply are at an absolute premium. Like the currently marketed LifeFlow PLUS, LifeFlow Ultra will enable healthcare providers to transfuse blood and IV fluids quickly for patients with hemorrhagic shock.

By promising efficiency in transfusing blood and IV fluids quickly for patients experiencing hemorrhagic shock LifeFlow Ultra has positioned itself among the key players in the market. This offering also makes them stand out as a valuable addition to the existing market, boosting the global rapid infuser market value.

Global Rapid Infuser Market: Competitor Landscape

In July 2023, BD (Becton, Dickinson and Company), a leading global medical technology company, announced that the updated BD Alaris™ Infusion System received 510(k) clearance from the U.S. Food and Drug Administration (FDA), which enables both remediation and a return to full commercial operations for the most comprehensive infusion system available in the United States.

This clearance covers updated hardware features for Point-of-Care Unit (PCU), large volume pumps, syringe pumps, patient-controlled analgesia (PCA) pumps, respiratory monitoring, and auto-identification modules. It also covers a new BD Alaris™ Infusion System software version with enhanced cybersecurity, along with interoperability features that enable smart, connected care with the most widely used electronic medical record (EMR) systems.

The key features of the rapid infuser market report include patent analysis, grants analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

• Becton, Dickinson and Company (BD)

• B. Braun Melsungen AG

• Smiths Medical (A division of Smiths Group)

• 3M Company

• Teleflex Incorporated

• Fresenius Kabi AG

• Stryker Corporation

• Smith Medical

• ZOLL Medical Corporation

• GE Healthcare

• Baxter International Inc.

• Halyard Health

• Ivenix, Inc.

• AngioDynamics, Inc.

• FiPerSys Medical

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Highlights of the Report